Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KZR-616 in AIHA and ITP
NCT04039477Phase 2Withdrawn
- Sponsor
- Kezar Life Sciences
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of zetomipzomib in autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), sponsored by Kezar Life Sciences. Planned start Jul 2020; status: withdrawn.
02
Drugs
zetomipzomib
03
Conditions
autoimmune hemolytic anemia (AIHA)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04039477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039477.